Wall Street analysts are recommending Rocket Lab as the closest public-market proxy for investors unable to purchase shares of SpaceX [1].
This shift in investor focus matters because SpaceX remains a private company, leaving a gap in the U.S. equity markets for commercial launch services. Rocket Lab is currently the only publicly traded launch company providing this specific exposure [1].
Financial data from the first quarter supports the company's growth trajectory. Rocket Lab reported Q1 revenue of $200.35 million [1]. This figure represents a year-over-year revenue growth of 63.5% [1].
Profitability metrics also showed improvement during the period. The company's non-GAAP gross margin rose to 43.0%, up from a previous 33.4% [1]. These margins reflect the scaling of their launch and space systems operations.
Future growth is anchored by a substantial backlog of work. The company currently holds a backlog valued at $2.20 billion [1]. This pipeline is supported by a steady stream of new agreements, including 31 Electron and HASTE contracts and five Neutron missions [1].
Rocket Lab shares are currently trading around $150 [1]. Analysts said the stock serves as a vehicle for those seeking a foothold in the expanding commercial space sector while waiting for a potential SpaceX public offering [1].
“Rocket Lab is currently the only publicly traded launch company providing this specific exposure”
The positioning of Rocket Lab as a 'SpaceX proxy' indicates a high investor appetite for the commercial space race that exceeds the current availability of public assets. While Rocket Lab's revenue growth and increasing gross margins signal operational maturity, the stock's valuation is heavily influenced by its status as the sole liquid alternative to a dominant private competitor.
